Melanoma
1,467
182
306
689
Key Insights
Highlights
Success Rate
74% trial completion
Published Results
336 trials with published results (23%)
Research Maturity
689 completed trials (47% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
16.1%
236 terminated out of 1467 trials
74.5%
-12.1% vs benchmark
6%
87 trials in Phase 3/4
49%
336 of 689 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 689 completed trials
Clinical Trials (1467)
Harvesting Cells for Experimental Cancer Treatments
Evaluation for NCI Surgery Branch Clinical Research Protocols
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma
Dabrafenib and/or Trametinib Rollover Study
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
A Study of QL1706 Combined With OH2 Injection in Perioperative Treatment of Stage III Resectable Acral Melanoma
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Clinical Genetics Branch Eligibility Screening Survey
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.
A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
A Study of BI 3810944 in Patients With Advanced Cancer
Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
DESTINY-PANTUMOUR04